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Zander et al. [1] have recently conducted a prospect-
ive observational study to describe the variability of
piperacillin (PIP) concentrations and target attainment
in a heterogeneous cohort of 60 critically ill patients.
An intermittent bolus dosing regimen of piperacillin-
tazobactam (PIP-TAZ) was used 4.5 g three times
daily (TID) or twice daily (BID), depending on renal
function.
As PIP-TAZ is largely renally excreted, it was unsur-
prising that the investigators found that no patient
within the highest quartile of creatinine clearance (CrCl)
attained specified pharmacokinetic/pharmacodynamic
(PK/PD) targets (trough concentrations ≥22.5 mg/L) on
days 1 or 4. These results are consistent with previous
data showing that ‘augmented renal clearance’ (ARC),
defined as a CrCl ≥130 mL/min [2], is frequently being
associated with subtherapeutic PIP concentrations, even
when dosing PIP-TAZ four times daily (QID) [2, 3]. Of
more interest, however, was that the investigators found
that 0 % and 55 % of patients with a CrCl >65 mL/min
and 30–65 mL/min, respectively, attained the target PIP
trough concentrations [1]. This is a very important find-
ing as it highlights that initiating TID PIP-TAZ dosing
as a blanket strategy in critically ill patients with ‘normal’
renal function or even mild to moderate renal impair-
ment will not reliably attain PK/PD targets. In line with
these findings, and perhaps reflective of the ongoing
challenges with dose optimization in this group of pa-
tients, previous work has shown QID dosing of PIP-TAZ
to be insufficient in achieving free PIP concentrations
that are four times the target minimum inhibitory
concentration (MIC) at 50 % of the dosing interval
(50%fT>4xMIC), even in patients not displaying ARC
[4, 5]. Solutions for target non-attainment of PIP-TAZ
in intensive care unit (ICU) patients include use of
prolonged infusions and therapeutic drug monitoring
(TDM).
Administering PIP-TAZ as a prolonged infusion—that
is, either administering the antibiotic over half the dos-
ing interval (e.g., over 3 h if given QID), or administer-
ing the total daily dose as a continuous infusion over
24 h after an initial loading dose—may help overcome
subtherapeutic PIP concentrations in the critically ill [6].
There are now observational studies as well as random-
ized controlled trial (RCT) data that show increased like-
lihood of PIP concentrations being maintained above the
MIC of pathogens using the prolonged infusion strategy
[7–9]. Furthermore, there were higher rates of clinical
cure associated with PIP-TAZ administered as a con-
tinuous infusion in the RCTs [7, 9]. Both of the RCTs in-
cluded patients with mild to moderate renal impairment,
and so, coupled with the results from the study by
Zander et al. [1] showing PK/PD target attainment being
problematic in these groups of patients via intermittent
bolus dosing, the use of prolonged infusions may be a
simple strategy that ICUs can employ. Notably, however,
prolonged infusions may still not achieve therapeutic
targets in certain groups of patients, such as those
displaying ARC [10]. In these circumstances, dose up-
titration may also be advisable, but can only be com-
fortably performed with use of TDM.
To this end, a major challenge in determining optimal
PIP-TAZ dosing for individual critically ill patients is the
high inter-patient variability in serum PIP trough con-
centrations. Zander and investigators noted a 123-fold
to >1785-fold range of PIP trough concentrations among
their study patients, which was more pronounced in pa-
tients with higher creatinine clearances than those with
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severely impaired renal function [1]. Other investigators
have also shown high inter-patient variability with
PIP-TAZ dosing [11, 12], albeit in studies with
smaller sample sizes of more homogeneous groups of
critically ill patients. From these PK data, as well as
due to pathogen-related factors such as decreasing
antibiotic susceptibilities, as reflected by higher MICs,
it is becoming evident that an individualized dosing
approach needs to be adopted in order to maximize
PIP-TAZ efficacy. Given this, there is significant scope
for TDM of PIP-TAZ as well as other beta-lactam an-
tibiotics in the ICU. Monitoring of trough concentra-
tions at a steady state (usually after 3 to 4 doses) is
generally recommended to see whether PK/PD targets
are being met [13]. Earlier measurement should be
preferred where dosing can be optimized using Bayesian
dosing software [14]. Additionally, measurement of the
‘free’ or unbound PIP concentrations, rather than ‘total’
concentrations as described by Zander et al. [1], is advised.
Although PIP is not highly protein bound (typically 30 %),
differences in protein binding among patients, particularly
those in hypoalbuminemic states, as well as alterations in
protein binding during assay preparation, means there is
much guess work determining PK/PD targets when using
‘total’ rather than ‘unbound’ antibiotic concentrations [15].
Interestingly, although Zander and colleagues found
intra-patient variability to be less than inter-patient vari-
ability in their study cohort, the coefficient of variations
(CV) for intra-patient PIP concentration variability was
still wide, ranging from 6.4 to 129 % (median of 30 %)
[1]. The heterogeneity of the study population most
likely contributed to this wide intra-patient variability;
however, the median CV for intra-patient variability is
comparable to the median CV of 40 % reported by
Carlier et al. [11], and reflects the key message that con-
sistent dosing of PIP-TAZ does not necessarily result in
consistent PIP concentrations throughout the period of
therapy. This suggests that the use of merely ‘once-off ’
TDM may be inadequate in determining if PK/PD tar-
gets are being attained consistently throughout therapy
duration. We believe this study and previous work make
the case for more frequent, perhaps even daily, use of
TDM to ensure ongoing efficacy of PIP-TAZ in the crit-
ically ill patient [11].
Conclusions
Zander and colleagues have provided new information
on target attainment of PIP concentrations in a hetero-
geneous group of critically ill patients. Among patients
without severe renal dysfunction, there are concerns of
not reaching PK/PD targets using traditional TID dosing
of PIP-TAZ. There also is high inter- and intra-patient
variability in PIP concentrations. Alternative dosing
strategies that optimize PIP-TAZ therapy are needed and
may include the use of prolonged infusions. Importantly,
there is strong rationale for the use of regular TDM to
be the cornerstone for individualizing PIP-TAZ therapy
and maximize efficacy.
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